Anthropic announced Claude Science in July 2026 at an event called “The Briefing: AI for Science” — a platform the company describes as an “AI workbench for scientists” that consolidates fragmented tools and datasets into a single environment and generates figures and visuals. Alongside the launch, the company said it intends to develop drugs of its own, with head of life sciences Eric Kauderer-Abrams stating the focus will be on treatments for “neglected” diseases.
The move puts Anthropic in the unusual position of selling software to drugmakers while potentially competing with them. The company joins a field that already includes AI-first drug companies like Insilico, Google DeepMind spinout Isomorphic Labs, and major pharmaceutical companies building or acquiring AI tools. OpenAI, Amazon, and Google also have their own life sciences platforms.
Anthropic has offered few specifics about its drug development plans. At the event, Kauderer-Abrams did not say what the company would do with any promising drug candidates it finds. Anthropic did not respond to requests for comment on which diseases it plans to target first, or whether it would partner with other companies for lab work, animal testing, clinical trials, or manufacturing. The company has, however, been hiring biologists and building its own wet labs, and several life sciences roles were listed as open at the time of reporting. Namshik Han, a professor at the University of Cambridge, said Anthropic has been “actively recruiting” in the area and has drawn candidates from Big Pharma and academic institutions.
Experts caution that any payoff is likely years away. Matthew Todd, a professor of drug discovery at University College London, said the field is “a long way off” from an AI-designed drug receiving regulatory approval, noting that drug candidates still require slow, methodical real-world testing for safety and efficacy. Frank von Delft, a professor at the University of Oxford, said AI models “haven’t yet come close to making experiments unnecessary” and that Anthropic is “going to have to spend a lot on experiments.” No AI-designed drug has yet completed clinical trials and reached market.
A new drug typically takes at least a decade to move through clinical trials, meaning any treatment Anthropic develops would be, at minimum, the better part of a decade from reaching patients.
Source: The Verge